NASDAQ:VIVE   Viveve Medical, Inc
VIVE - SEP 23,

fundamentally,

Viveve Announces Issuance of New Method Patent for Stress Urinary Incontinence in Australia

technically ;

has a target at 2.45

SL = 2.35

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.